Author: Ravi Shankar

Salvatore A. Abbate appointed President and Chief Executive Officer

Third quarter results reflect significant underperformance in Europe

Alvarez & Marsal retained to advise Company on European operations

Withdraws full-year 2026 guidance

ANTIOCH, Tenn., Oct. 23, 2026 (GLOBE NEWSWIRE) — LKQ Corporation (Nasdaq: LKQ) today announced preliminary, unaudited results for the third quarter ended September 30, 2026, as well as leadership and operational actions intended to address recent performance and position the Company for improved execution under new leadership.

Preliminary Third Quarter 2026 Results

Based on preliminary unaudited financials for the third quarter, LKQ expects to report the following:

• Revenue of $3.32 billion, compared with $3.50 billion in the third quarter of 2025
   
• Parts and services organic revenue decline of 5.4%
   
• Net loss¹ of $16 million to $32 million, including $111 million of non-cash impairment charges, compared with net income¹ of $178 million in the third quarter of 2025
   
• Diluted loss per share¹ of $0.06 to $0.12, including $0.42 per share of non-cash impairment charges, compared with diluted EPS of $0.69 in the third quarter of 2025
   
• Adjusted diluted EPS^1,2 of $0.47 to $0.53, compared with $0.84 in the third quarter of 2025
   
• Europe parts and services organic revenue decline of 9.8%; and segment EBITDA margin of 4.1% to 5.1%, compared with 10.0% in the third quarter of 2025

The third quarter results primarily reflect underperformance in the Europe segment, including operational disruptions associated with the ERP implementation in Germany and volume declines in the United Kingdom and Benelux. While Specialty was modestly below expectations, the shortfall was more limited, and North America performed in line with the Company’s expectations despite softer market conditions.

The Company will report full third quarter results on October 29, 2026, and will hold a conference call at that time.

Leadership Changes

LKQ today announced the appointment of Salvatore A. Abbate as President and Chief Executive Officer, effective December 15, 2026. He succeeds Justin Jude, who is departing the Company effective today. Until Mr. Abbate assumes the role of President and Chief Executive Officer, the Company has established an interim Office of the Chief Executive Officer to provide ongoing leadership continuity, consisting of John Mendel, Chairman of the Board, and Sue Gove, Chair of LKQ’s Audit Committee. The Office of the Chief Executive Officer will work closely with LKQ’s leadership team in overseeing the Company’s operations during the interim period.

(1) References in this release to Net (loss) income and Diluted (loss) earnings per share, and the corresponding adjusted figures, reflect amounts from continuing operations attributable to LKQ stockholders.

(2) Non-GAAP measure. See the table accompanying this release that reconciles the actual or forecasted U.S. GAAP measure to the actual or forecasted adjusted measure, which is non-GAAP.

Also effective today, Andy Hamilton is departing his role as President and Managing Director of LKQ Europe. The Board has engaged Alvarez & Marsal (“A&M”) to advise the Company on its European operations, with an initial focus on improving customer service levels, stabilizing operations and strengthening performance and cost discipline across the region.

“LKQ’s performance, particularly in Europe, has fallen significantly short of the Board’s expectations, and the Board is taking decisive action to address it,” said John Mendel, Chairman of the Board. “We have strong conviction in LKQ’s business and its potential to create significant value for shareholders. Sal is a proven operator with a track record of driving performance in complex distribution businesses, and A&M brings deep experience in operational improvement. Together with LKQ’s talented teams, we are focused on improving execution and delivering improved results for our stakeholders.”

Withdrawal of Full-Year 2026 Guidance

Considering the third quarter results in Europe and the appointment of Mr. Abbate as President and Chief Executive Officer, effective December 15, 2026, LKQ is withdrawing its full-year 2026 guidance, which was most recently updated on July 30, 2026.

Strategic Review Update

In connection with the Board’s ongoing review of strategic alternatives, the Company has taken several actions, including appointing Mr. Abbate as the Company’s next President and Chief Executive Officer, implementing leadership changes within its European operations, and retaining A&M to advise the Company with respect to its European operations. The Company will provide additional updates regarding the strategic alternatives process as appropriate.

About LKQ Corporation

LKQ Corporation (www.lkqcorp.com) is a leading provider of alternative and specialty parts to repair and accessorize automobiles and other vehicles. LKQ has operations in North America, Europe and Taiwan. LKQ offers its customers a broad range of OE recycled and aftermarket parts, replacement systems, components, equipment, and services to repair and accessorize automobiles, trucks, and recreational and performance vehicles.

The following unaudited table reconciles Net (Loss) Income and Diluted (Loss) Earnings per Share to Adjusted Net Income and Adjusted Diluted (Loss) Earnings per Share, respectively:

	Three Months Ended September 30,
	2026							2025
	Preliminary
(In millions, except per share data)		Low			High
Net (loss) income	$	(35	)	$	(19	)	$	180
Less: net (loss) income attributable to continuing noncontrolling interest		(1	)		(1	)		—
Net (loss) income attributable to LKQ stockholders		(34	)		(18	)		180
Less: net (loss) income from discontinued operations		(2	)		(2	)		2
Net (loss) income from continuing operations attributable to LKQ stockholders		(32	)		(16	)		178
Adjustments:
Amortization of acquired intangibles		34			34			37
Restructuring and transaction related expenses		24			24			14
Impairment of goodwill		88			88			—
Impairment of net assets held for sale		23			23			—
Direct impacts of Ukraine/Russia conflict		4			4			—
Excess tax deficiency from stock-based payments		1			1			—
Tax effect of adjustments		(23	)		(23	)		(13	)
Adjusted net income	$	119		$	135		$	216
Weighted average diluted common shares o/s		252.9			252.9			257.3
Diluted (loss) earnings per share:
Reported	$	(0.12	)	$	(0.06	)	$	0.69
Adjusted	$	0.47		$	0.53		$	0.84

We have presented Adjusted Net Income and Adjusted Diluted Earnings per Share as we believe these measures are useful for evaluating the core operating performance of our continuing business across reporting periods and in analyzing our historical operating results. We define Adjusted Net Income and Adjusted Diluted Earnings per Share as Net Income and Loss and Diluted Earnings (Loss) per Share adjusted to eliminate the impact of net income and loss attributable to noncontrolling interest, income and loss from discontinued operations, restructuring and transaction related expenses, amortization expense related to all acquired intangible assets, gains and losses on debt extinguishment, changes in fair value of contingent consideration liabilities, other gains and losses related to acquisitions, equity method investments, or divestitures, impairment charges, direct impacts of the Ukraine/Russia conflict, excess tax benefits and deficiencies from stock-based payments and any tax effect of these adjustments. The tax effect of these adjustments is calculated using the effective tax rate for the applicable period or for certain discrete items the specific tax expense or benefit for the adjustment. These financial measures are used by management in its decision making and overall evaluation of our operating performance and are included in the metrics used to determine incentive compensation for our senior management. Adjusted Net Income and Adjusted Diluted Earnings per Share should not be construed as alternatives to Net Income and Loss or Diluted Earnings (Loss) per Share as determined in accordance with accounting principles generally accepted in the United States. In addition, not all companies that report measures similar to Adjusted Net Income and Adjusted Diluted Earnings per Share calculate such measures in the same manner as we do and, accordingly, our calculations are not necessarily comparable to similarly-named measures of other companies and may not be appropriate measures for performance relative to other companies.

Forward-Looking Statements

Statements and information in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are made pursuant to the “safe harbor” provisions of such Act.

Forward-looking statements include, but are not limited to, statements regarding our outlook, expectations, beliefs, hopes, intentions and strategies. These statements are subject to a number of risks, uncertainties, assumptions and other factors including those identified in our filings with the SEC. All forward-looking statements are based on information available to us at the time the statements are made. We undertake no obligation to update any forward- looking statements, whether as a result of new information, future events or otherwise, except as required by law.

You should not place undue reliance on our forward-looking statements. Actual events or results may differ materially from those expressed or implied in the forward-looking statements. The risks, uncertainties, assumptions and other factors that could cause actual events or results to differ from the events or results predicted or implied by our forward- looking statements include the factors discussed in our filings with the SEC, and other factors discussed in our filings with the SEC, including those disclosed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025 and in our subsequent Quarterly Reports on Form 10-Q. These reports are available at the Investor Relations section on our website (www.lkqcorp.com) and on the SEC’s website (www.sec.gov). 

Preliminary Financial Information

The preliminary third quarter financial highlights presented in this press release are derived from our internal records and based on the most recent current information available to management, are subject to the closing and finalization of financial and accounting procedures for the period (which have yet to be performed) and should not be viewed as a substitute for our full financial statements prepared in accordance with GAAP. Our normal reporting processes with respect to the preliminary estimated financial data provided in this press release have not been fully completed. As a result, these preliminary estimated results may differ from the actual results that will be reflected in our unaudited condensed consolidated financial statements for the third quarter of 2026 when they are completed. While we believe that these estimates are based on reasonable assumptions, our actual results may vary, and such variations may be material.

Investor Contact

Joseph P. Boutross LKQ Corporation
Vice President, Investor Relations
(312) 621-2793
jpboutross@lkqcorp.com

Media Contact

Whit Clay
Longacre Square Partners
lkq@longacresquare.com

MEDELLÍN, Colombia, Oct. 23, 2026 (GLOBE NEWSWIRE) — Mineros S.A. (TSX: MSA; BVC: MINEROS; OTCQX: MNSAF) (“Mineros” or the “Company”) announces that its Board of Directors has called an extraordinary meeting of shareholders (the “Meeting”). The Meeting will be held at 10:00 a.m. (Colombia time) on November 24, 2026, in the Salón Gran Real of the Hotel Marriott, Calle 1a Sur #43a-83, Medellín, Antioquia, Colombia.

The matters to be voted on or addressed at the Meeting are as follows:

1. Verification of quorum and introduction to the Meeting.
2. Approval of the Meeting agenda.
3. Appointment of the commission for the scrutiny, review and approval of the minutes of the Meeting.
4. Approval of the release of occasional reserves and distribution of the amount released to shareholders as an extraordinary dividend.

Proposed Extraordinary Dividend

At the Meeting, shareholders will be asked to approve the release of a portion of the Company’s occasional reserves, constituted out of profits of fiscal years ended on or before December 31, 2025, and the distribution of the released amount as a one-time extraordinary cash dividend of US$0.20 per common share (the “Extraordinary Dividend”).

If approved, the Extraordinary Dividend will be payable in a single instalment on December 4, 2026, to shareholders of record on December 1, 2026. It is in addition to, and does not affect, the ordinary dividend of US$0.10 per share approved on March 27, 2026. The Board recommends that shareholders vote FOR the resolution.

Dividends paid to shareholders holding through the Canadian system will be subject to a 20% Colombian withholding tax. Eligible shareholders may claim any excess withholding through the procedure described in the Management Information Circular dated October 15, 2026 (the “Circular”).

Meeting Materials and Voting

The record date for shareholders in the Canadian market is October 15, 2026. To be valid, proxies and voting instruction forms must be received by TSX Trust Company no later than 10:00 a.m. (Colombia time) on November 20, 2026.

The Company is using notice-and-access. The Circular and related materials are available on SEDAR+ at www.sedarplus.com, at https://docs.tsxtrust.com/MSA2026, and on the Company’s website at www.mineros.com.co. A live listen-only webcast of the Meeting will be available on the Company’s website.

About Mineros S.A.
Mineros is a leading Latin American gold producer headquartered in Medellín, Colombia. The Company benefits from a diversified asset portfolio, encompassing operating mines in Colombia and Nicaragua, alongside a pipeline of development and exploration projects located throughout the region, including the Porvenir development asset in Nicaragua, the La Pepa Project in Chile and the Tolima Project in Colombia.

With an operating history spanning over 50 years, Mineros is defined by a commitment to safety, sustainability, and disciplined capital allocation. Its common shares are listed on the Toronto Stock Exchange (MSA) and the Colombia Stock Exchange (MINEROS), and trade on the OTCQX® Best Market under the symbol MNSAF.

For Further Information
Ann Wilkinson | Vice President, Investor Relations
+1 (647) 496-3011 | Ann.Wilkinson@Mineros.com.co

Juan Camilo Obando | Director, Investor Relations
(+57) 604 266 5757 | Juan.Obando@Mineros.com.co

Forward-Looking Statements
This news release contains forward-looking information within the meaning of applicable Canadian securities laws, including statements with respect to the approval, declaration, timing, amount and payment of the Extraordinary Dividend, the amount of occasional reserves available for distribution, the expected tax treatment of the Extraordinary Dividend. Forward-looking information is based upon estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this news release including, without limitation, assumptions about: the approval of the Extraordinary Dividend by the General Shareholders Assembly; the Company’s financial condition, liquidity and cash flows; the absence of restrictions on the payment of dividends under the Company’s financing arrangements; legal, regulatory and tax stability in Colombia and Canada; and the number of common shares outstanding on the record date. While the Company considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking information. Forward-looking information involves known and unknown risks, uncertainties and other factors, and does not guarantee future performance. Risks and uncertainties that may cause actual results or developments to be materially different from those expressed in forward-looking information include, without limitation: the General Shareholders Assembly may not approve the Extraordinary Dividend, or may approve it with variations; laws, regulations and tax rates may change; and the Company’s financing arrangements may restrict the payment of dividends. This list is not exhaustive. There can be no assurance that forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information contained herein is made as of the date of this news release. The Company disclaims any obligation to update or revise any forward-looking information, except as required by applicable securities laws.

HONG KONG, Oct. 23, 2026 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today entered into a subscription agreement (the “Subscription Agreement”) with 3E NETWORK TECHNOLOGY PTE. LTD., a company incorporated under the laws of Singapore (the “Yang Investor”), and six individual purchasers (collectively with the Yang Investor, the “Purchasers”), for a private placement (the “Private Placement”) of an aggregate of 2,751,789 Class A ordinary shares, par value $0.005 per share, of the Company (the “Class A Ordinary Shares”), at a purchase price of approximately US$1.8170 per share, for aggregate gross cash proceeds to the Company of $5,000,000. On October 23, 2026, the Company announced a two-for-one share consolidation, with its Class A Ordinary Shares expected to begin trading on a post-consolidation basis on October 30, 2026 (the “Nasdaq Market Effective Date”). These share numbers, the par value and the per-share purchase price are stated on a post-consolidation basis.

Under the Subscription Agreement, the Yang Investor agreed to subscribe for 1,157,823 Class A Ordinary Shares for $2,103,764.12, and each of the six individual purchasers agreed to subscribe for 265,661 Class A Ordinary Shares for $482,705.98, in each case on a post-consolidation basis. Each Purchaser’s obligations are several and not joint. The issuance of the Class A Ordinary Shares under the Subscription Agreement is subject to satisfaction of the applicable conditions thereunder and will not occur before the Nasdaq Market Effective Date.

The Class A Ordinary Shares to be issued and sold under the Subscription Agreement will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and will be offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D thereunder. The Company is relying on such exemption based in part on the Purchasers’ representations, including that each Purchaser is an accredited investor. The Class A Ordinary Shares may not be offered or sold absent registration or an applicable exemption from registration requirements. Neither this press release nor the related Report on Form 6-K constitutes an offer to sell or the solicitation of an offer to buy the securities described herein.

The Yang Investor is controlled by Dr. Tingjun Yang (“Dr. Yang”), the Company’s Chief Executive Officer and a director, and its subscription in the Private Placement constitutes a related-party transaction. The Audit Committee of the Board of Directors reviewed and approved the Private Placement, including the Yang Investor’s participation as a related-party transaction, and recommended approval by the Board of Directors. The Board of Directors approved the Private Placement and the transactions contemplated by the Subscription Agreement. Other than the Yang Investor, none of the Purchasers has any affiliation with or other interest relationship with the Company or its directors or officers.

The Company intends to use the proceeds from the Private Placement for general working capital, ordinary course business operations and other lawful corporate purposes determined by the Company in its reasonable discretion, in compliance with applicable laws and regulations.

About 3 E Network Technology Group Limited
3 E Network Technology Group Limited is a business-to-business (“B2B”) information technology (“IT”) business solutions provider committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider. It upholds the industry consensus of “AI and energy symbiosis” and has a strong vision in the field of energy investment. The Company’s business comprises two main portfolios: the data center operation services portfolio and the software development portfolio. For more information, please visit the Company’s website at https://3emask.com/.

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect the Company’s future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

3 E Network Technology Group Limited
Investor Relations Department
Email: ird@3emask.com
Website: https://3emask.com/

Preclinical data demonstrate tumor response with AVA6103 in the setting of Enhertu^®-resistance

Potential for prolonged responses with increased FAP+ fibroblasts recruited to the tumor during treatment with AVA6103

LONDON and PHILADELPHIA, Oct. 23, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces the presentation at the European Society for Medical Oncology (ESMO) Congress of the FOCUS-01 Phase 1 clinical trial design and substantial progress in the preclinical arena. AVA6103 is the first Next-Generation pre|CISION^® controlled-release peptide-drug conjugate platform (PDC), a fibroblast activation protein (FAP)-activated exatecan (Exd) PDC, designed to deliver payload to tumors with similar kinetics of antibody drug conjugates (ADCs) using small molecule chemistry.

AVA6103 is designed to significantly increase the therapeutic window of its highly potent payload, exatecan, a topoisomerase 1 inhibitor (TOP1i) similar to the deruxtecan payload of Enhertu^®. The Company highlights preclinical data demonstrating superior disease control by AVA6103 compared with Enhertu^® in a patient-derived xenograft (PDX) mouse model with HER2+/FAP+ gastric tumors that progressed after initial treatment with Enhertu^®, resulting from enhanced cleavage potential with recruitment of FAP+ fibroblasts during treatment with AVA6103.

Dave Liebowitz, Chief Medical Officer of Avacta, commented:

“AVA6103’s continued ability to shrink HER2+ gastric tumors after progression on Enhertu^® demonstrates the potential of pre|CISION^® PDCs to deliver sustained antitumor activity in preclinical models, well beyond the time points achievable with ADCs, showing the potential to improve outcomes for patients with aggressive cancers.

These results add to a growing body of evidence suggesting that pre|CISION^® PDCs are not vulnerable to antigen loss, a phenomenon known to limit the efficacy of ADCs such as Enhertu^® over time, which is demonstrated here in our results. We observed persistent expression of FAP in the tumor through fibroblast recruitment, which is most likely mechanism for increased payload delivery over time on treatment.”

“These findings build further on our initial Phase 1a data with AVA6103 demonstrating proof of mechanism, with a clean safety profile thus far and exceptional alignment between preclinical modeled and clinical pharmacokinetic data, with controlled exatecan release evident in patients for days after dosing. The FOCUS-01 trial continues to progress well towards tumor PK in late Q4 2026 or early Q1 2027 and the first efficacy data, which we expect in H1 2027.”

Alexander Spira MD, PhD, FACP, FASCO, Lead author at ESMO, Co-Director, Virginia Cancer Specialists (VCS) Research Institute and one of the lead investigators of the trial, commented:

“The FOCUS-01 trial is moving rapidly and we are happy to partner with Avacta on this exciting new drug. The preclinical and translational data we have seen thus far reinforce our excitement around this mechanism of action.”

Key Preclinical and Translational Findings with AVA6103

Preclinical data demonstrate that AVA6103 is shows better antitumor activity than Enhertu^® in FAP-positive / HER2-positive disease, including in advanced and resistant tumors.

• In an early stage model (animals randomized once tumors reach 100-200mm³), all AVA6103-treated animals achieved partial responses, with tumor growth inhibition more than double that of Enhertu^®
• In animals with large established tumors (randomized at 400-500mm³), AVA6103 inhibited tumor growth and achieved partial responses, while Enhertu^® demonstrated limited activity
• All AVA6103-treated animals that had previously progressed on Enhertu achieved stable disease, while all animals retreated with Enhertu^® progressed

Tumor tissue studies from this experiment demonstrate that tumors treated with AVA6103 have increased FAP expression over time via immunohistochemistry, with recruitment of FAP+ fibroblasts over the course of treatment. Transcriptomic analysis via RNA seq studies revealed that AVA6103 induced a coordinated inflammatory, wound-healing response, with an upregulation of pathways involved with damage repair, cell cycle arrest, and extracellular matrix (ECM) reorganization.

FOCUS-01: Trial in Progress

The FOCUS-01 Phase 1a trial is a first in-human, multicenter dose escalation trial of AVA6103 and is enrolling patients with select tumor types predicted to be sensitive to the payload exatecan, based on co-expression of FAP and SLFN11, a gene known to predict response to the Topoisomerase 1 inhibitor mechanism.

Preliminary safety and pharmacokinetic (PK) data from the first three dose levels of the FOCUS-01 trial, reported in September, demonstrated proof of mechanism in patients treated in the first three cohorts in the trial. AVA6103 demonstrated a favorable safety profile and was well tolerated through the first three dose levels up to a payload dose approximately 50% higher than the maximum tolerated dose (MTD) of conventional exatecan.

The pharmacokinetic data of the PDC, released peptide and released exatecan patients were remarkably consistent with predictive PK modelling based on preclinical data, greatly increasing confidence that the safety profile, tumor selectivity and antitumor efficacy observed in the preclinical studies of AVA6103 will translate into the clinic.

Enrollment is ongoing in both arms of the study, with enrollment completed at dose level 4, representing an absolute dose of payload that is more than double the maximum tolerated dose (MTD) of conventional exatecan and approaches the equivalent topoisomerase I inhibitor payload dose of the approved dose of Enhertu^® in breast cancer.

Details of the poster presentation

A phase I trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre|CISION^® peptide-drug conjugate delivering sustained tumor microenvironment (TME) release of exatecan in patients with FAP-positive solid tumors
Authors: Alexander I. Spira, Nehal J. Lakhani, Judy S. Wang, Muhammad R. Khawaja, Ruairidh Edwards, Karen Campbell, Curtis Rink, Christiana Nikolova, David Liebowitz
Poster number: 1134eTiP

The poster can be found on Avacta’s website here.

Enhertu^® (trastuzumab deruxtecan; T-DXd) is a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product). Enhertu^® is a registered trademark of Daiichi Sankyo Company, Limited and AstraZeneca.

For further information from Avacta, please contact:

Avacta Group plc Christina Coughlin, Chief Executive Officer	https://avacta.com/ via Cohesion Bureau
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance	www.strandhanson.co.uk
Zeus (Broker) James Hornigold / George Duxberry (Investment Banking) Dominic King / Alex Bartram (Corporate Broking)	www.zeuscapital.co.uk
Cohesion Bureau Communications / Media / Investors Chris Maggos	avacta@cohesionbureau.com

About Avacta – https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION^® platform. pre|CISION^® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta’s innovative pre|CISION^® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

Our pre|CISION^® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION^® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer.

About FAP-Exd (AVA6103)

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION^® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

MILWAUKEE, Oct. 23, 2026 (GLOBE NEWSWIRE) — Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, today announced that Raj Seshadri will join the Fiserv Board of Directors effective November 30, 2026. The Company also announced that Henrique De Castro would not seek reelection to the Board at the Company’s annual meeting of shareholders in 2027.

Seshadri currently serves as Senior Strategic Advisor to the Chief Executive Officer of Mastercard Inc. where she advises on emerging strategic priorities. Over her more than a decade career at Mastercard, Seshadri served as Chief Commercial Payments Officer, leading one of Mastercard’s largest growth businesses encompassing commercial cards, B2B accounts payable and receivable solutions, bill payments, remittances, and disbursements. Before leading Commercial Payments, Seshadri served as President of Mastercard’s Data & Services business, overseeing a global portfolio of analytics, insights, loyalty, cybersecurity, and innovation solutions. She also served as President of U.S. Issuers, where she led relationships with many of the nation’s largest financial institutions.

Seshadri has also held numerous senior leadership positions at BlackRock, Citigroup, U.S. Trust, and McKinsey & Company. She currently serves on the Board of Directors of Raymond James Financial, Inc.

“Raj is a highly respected financial services and payments leader whose career has been defined by driving growth, innovation, and strategic transformation across banking, payments, and data analytics,” said Gordon Nixon, Chairman of the Board of Directors. “As we continue to accelerate innovation at the intersection of banking, and commerce, Raj’s insights and perspective will be a tremendous asset to Fiserv and our Board.” Nixon concluded, “We are grateful to Henrique for his service on the Board and his lasting contributions. We thank him for his thoughtful counsel over many years.”

Seshadri’s appointment is consistent with the Board’s ongoing commitment to having the right mix of skills to advance Fiserv’s strategy and further enhances the Board’s collective expertise as Fiserv unites commerce and finance, powering sustained growth and innovation at scale for financial institutions and businesses around the world.

About Fiserv
Fiserv, Inc. (NASDAQ: FISV), a Fortune 500 company, is a global leader uniting commerce and finance. The company powers sustained growth and innovation at scale for financial institutions and businesses worldwide across payments, account processing, digital banking, merchant acquiring, network services, e-commerce, and Clover®, the all-in-one business management platform. Fiserv is a member of the S&P 500® Index and one of FORTUNE® America’s Most Innovative Companies. Visit fiserv.com and follow on social media for more information and the latest company news. 

For more information contact:

Media Relations: Melissa Moritz Vice President, Communications Fiserv, Inc. melissa.moritz@fiserv.com

Additional Contact: Walter Pritchard SVP, Investor Relations Fiserv, Inc. walter.pritchard@fiserv.com

A 1,500 MW Combined Renewable Natural Gas and Biomass Power Plant and Water Supply Project Valued at Up to $1.66 Billion; Azure Holds a 10% Equity Stake

Fort Lauderdale, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME), a diversified holding company and owner of Azure Energy (“Azure”), a strategic advisor to renewable power plant developers, and SemiCab Holdings, an AI-enabled logistics provider, today provided an operational update on a 1,500 MW combined renewable natural gas and biomass power plant project in Mississippi. Engineering for the project is nearly complete, and it is being marketed to potential tenants, including data centers and advanced manufacturing facilities, that would co-locate on site.

The $7.34 billion project will sit on a 1,664-acre site in north-central Mississippi. It combines 500 MW of net generation from a biomass pyrolysis-to-power (Azure P2P^™) plant, 1,000 MW of natural gas generation, and a 150,000-ton absorption chilled water plant. All output will be delivered behind the meter to a single co-located large-load tenant, such as a hyperscale data center or advanced manufacturing facility. The campus is expected to become operational in three phases, with the first phase delivering approximately 250 MW of power within 18 months of notice to proceed. The facility is expected to reach its full generation capacity within 54 months of notice to proceed. Local development partners have secured feedstock through a right of first refusal and a memorandum of understanding. Phase II engineering is scheduled for completion in October 2026, and the Independent Engineer report is due in December 2026.

Azure expects to earn approximately $5 million in fee income in 2027 under the current scope of engagement, with additional fee income opportunity under negotiation. Azure currently holds a 10% equity stake in the project. The project has two clearly defined paths to unlock value. First, if the project is completed as scheduled, Azure is projected to earn approximately $40 million in EBITDA annually from the project once it reaches full operation.

Alternatively, the project could be sold upon the completion of final permitting in early 2027, with an estimated value of up to $1.66 billion based on prevailing market conditions. If sold as valued, the gross proceeds due to Azure would be approximately $166 million for its equity stake, plus additional fee income for managing the transaction. The Company expects to select capital markets partners before the end of Q4 2026 to evaluate offers. Full marketing of the project is expected to begin in early Q1 2027.

“Our Mississippi project is large in scale and in the final stage of preparation for market,” said Andrew Thompson, CEO of Algorhythm Holdings. “Potential capital markets partners have responded well, and we are now deciding how best to launch a comprehensive marketing process.”

“Shovel-ready sites with power and water already solved are increasingly scarce,” added Mr. Thompson. “This site offers a 1,500 MW power solution using biomass and renewable natural gas, with engineering nearly complete and water supply addressed. We expect strong interest from data center and advanced manufacturing tenants in the coming months.”

About Algorhythm Holdings

Algorhythm Holdings, Inc. is a holding company with two primary assets: Azure Holdings and SemiCab Holdings. Azure Energy provides strategic and technical advisory services for renewable biomass power generation infrastructure. Azure launched in 2025 and has already secured equity participation valued at over $220 million in net present value through multiple power plants under development in the US. The Company has significant fee-income consulting revenues under multi-year contracts and is generating growing, positive EBITDA. For additional information, please go to: http://www.azure-energy.co.

Algorhythm Holdings, Inc. also owns and operates SemiCab, an AI-enabled logistics software provider. Since 2020, SemiCab has enabled major retailers, brands, and transportation providers to address common supply-chain problems globally. Its AI-enabled, cloud-based Collaborative Transportation Platform achieves the scalability required to predict and optimize millions of loads and hundreds of thousands of trucks. SemiCab uses real-time data from API-based load tendering and pre-built integrations with TMS and ELD partners to orchestrate collaboration across manufacturers, retailers, distributors, and their carriers. SemiCab uses AI/ML and advanced optimization models to enable fully loaded round trips. With SemiCab’s AI platform, shippers pay less and carriers make more without having to change a thing. For additional information, please go to: http://www.semicab.com.

Investor Relations Contact

Brendan Hopkins
407-645-5295
investors@algoholdings.com
www.algoholdings.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in Algorhythm’s reports to the SEC, including, without limitation, Algorhythm’s Annual Report on Form 10-K for the year ended December 31, 2025. You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this press release to conform our statements to actual results or changed expectations, or as a result of new information, future events or otherwise.

BEND, Ore., Oct. 23, 2026 (GLOBE NEWSWIRE) — BranchOut Food Inc. (Nasdaq: BOF) (“BranchOut” or the “Company”), a growth-stage consumer packaged foods company focused on developing, manufacturing, marketing and distributing clean-label, plant-based dried fruit and vegetable snacks, today announced the pricing of an underwritten public offering of 2,941,177 shares of its common stock at a public offering price of $1.70 per share (the “Offering”). Gross proceeds to the Company, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $5.0 million. All of the shares in the Offering are to be sold by the Company.

Lake Street Capital Markets, LLC is acting as the representative of the underwriters for the Offering. The Company has granted the representative a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the Offering solely to cover over-allotments.

The Offering is expected to close on or about October 26, 2026, subject to satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes, including operating expenses and capital expenditures.

The shares of common stock are being offered pursuant to a registration statement on Form S-3 (File No. 333-299400), which was declared effective by the Securities and Exchange Commission (the “SEC”) on October 16, 2026. The Offering is being made only by means of a prospectus supplement and accompanying prospectus forming a part of the registration statement. A prospectus supplement relating to and describing the terms of the Offering will be filed with the SEC and will be available free of charge on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and accompanying prospectus may also be obtained, when available, from Lake Street Capital Markets, LLC, 121 South 8th Street, Suite 1000, Minneapolis, Minnesota 55402, by telephone at (612) 326-1305 or by email at capitalmarkets@lakestreetcm.com.

Disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About BranchOut Food Inc.

BranchOut Food Inc. (Nasdaq: BOF) is a leading international food technology company specializing in the production of high-quality dehydrated fruit- and vegetable-based products through its proprietary GentleDry™ technology. This next-generation dehydration method is designed to preserve the nutrition, quality and taste of fresh produce. BranchOut’s technology enables the Company to serve branded, ingredient and private-label customers. For more information, visit www.branchoutfood.com or follow BranchOut Food on social media.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Offering, the expected grant and potential exercise of the over-allotment option, the Company’s expected use of proceeds and the timing, size, terms and completion of the Offering. Forward-looking statements are generally identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would” and similar expressions. These forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including market conditions; the Company’s ability to complete the Offering on acceptable terms or at all; volatility in the market price of the Company’s common stock; the satisfaction of customary closing conditions; and the other risks and uncertainties described under “Risk Factors” in the prospectus supplement relating to the Offering and in the Company’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.

For more information:

ir@branchoutfood.com

SOURCE BranchOut Food Inc.

– The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaningful new option.”

– In a planned interim analysis, women implanted with the ATEV averaged 220 catheter-free days in the first year compared to 129 days with arteriovenous fistula, meeting the trial’s primary endpoint of superiority.

– ATEV recipients achieved functional access significantly faster than AV fistula recipients, with a median of 1.7 months compared to 5.3 months with an AV fistula.

DURHAM, N.C., Oct. 23, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that positive interim results from the V012 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous (AV) access for female hemodialysis patients were presented at the American Society of Nephrology’s (ASN) Kidney Week 2026, one of the world’s premier nephrology meeting, held this year in Denver, Colorado. V012 is the first randomized clinical trial specifically designed to evaluate the ATEV against AV fistula for hemodialysis access in women with end-stage kidney disease (ESKD).

In the V012 Phase 3 trial, women implanted with the ATEV achieved functional access more than three months sooner and spent significantly more time free of dialysis catheters over the first year than women who received an AV fistula, which is the current standard of care for hemodialysis access across all patients. Women have historically had poorer outcomes with AV fistula procedures, including higher rates of maturation failure, longer times to functional access, and greater reliance on infection-prone catheters.

The late-breaking podium presentation, delivered in the Late-Breaking Research Orals: Dialysis and Transplantation session, titled “Randomized Controlled Trial of an Acellular Tissue Engineered Vessel vs. Arteriovenous Fistula for Hemodialysis Access in Female Patients with ESKD: A Phase 3 CLN-PRO-V012 Interim Analysis,” was presented on Thursday, October 22, 2026 by Prabir Roy-Chaudhury, M.D., Ph.D., FASN, 2025 President of the American Society of Nephrology and Co-Director of the University of North Carolina Kidney Center.

“Every woman in this study was judged by her surgeon to be a candidate for a fistula, but more than a third of those fistulas failed to mature within a year in this study,” said Dr. Roy-Chaudhury. “That tells us that even in the right patients, we cannot count on a fistula to work, or to work in time. In V012, women with the ATEV reached usable access months sooner and spent significantly less time on a catheter. These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaningful new option for the patients who need it most.”

The V012 Phase 3 trial (NCT05908084) is a comparative study designed to enroll approximately 150 female hemodialysis patients, randomized 1:1 to receive either the ATEV or an AV fistula for hemodialysis access. All women enrolled were receiving hemodialysis through a catheter and were considered suitable candidates for AV fistula creation in the judgment of their treating surgeons. The primary efficacy endpoint is catheter-free days from access creation through 365 days, or until access abandonment, whichever occurs first. Results reflect a prespecified interim analysis of the first 80 patients. Because the trial met its primary endpoint, enrollment was stopped.

In the interim analysis, women implanted with the ATEV averaged 91 more catheter-free days over the first 12 months than women receiving an AV fistula (220.4 days compared to 129.3 days; p<0.001). Despite all patients being judged at the outset as suitable for fistula creation, only approximately 65% of AV fistulas achieved functional maturation by Month 12, with maturation largely plateauing by Month 9, leaving approximately one-third of women in the fistula arm without a functionally mature fistula at one year.

“Prolonged catheter dependence is one of the most serious problems a surgeon encounters in dialysis care. A bioengineered vessel that women can use sooner, and that keeps them off a catheter longer, could make a real difference,” added Mohamad A. Hussain, M.D., Ph.D., a vascular and endovascular surgeon-scientist at the Heart and Vascular Institute, Mass General Brigham, and Associate Professor of Surgery at Harvard Medical School.

“For a woman receiving maintenance hemodialysis, it’s important to have vascular access options that can be individualized to meet their needs. Less is more when it comes to getting women to usable access sooner – less catheter time is more time to enjoy non dialysis activities without having to worry about the risks of catheter-related infection, hospital visits, and uncertainty.” said Charmaine Lok, M.D., Professor of Medicine at the Faculty of Medicine, University of Toronto and Senior Scientist at the Toronto General Hospital Research Institute.

The safety profile of the ATEV was comparable to that of AV fistula. Fewer dialysis access infections were observed with the ATEV, approximately 6 per 100 patient-years, compared to 23 per 100 patient-years with AV fistula. None of the infections in the ATEV group were related to the vessel itself, and no spontaneous ruptures were reported in either group.

The results from V012, supported by the results from two previously completed Phase 3 trials in hemodialysis access, form the clinical foundation for Humacyte’s planned supplemental Biologics License Application to expand the Symvess® label to include AV access for hemodialysis, which the Company has targeted for submission to the FDA this quarter.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our plans, anticipated timeline and ability to file applications for, and obtain marketing approvals from, the FDA and other regulatory authorities, including the European Medicines Agency, for our ATEVs and product candidates; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding the results of our clinical trials, including our V012 Phase 3 clinical trial, and regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs and the public perception thereof; the implementation of our business model and strategic plans for our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and Form 10-Q for the quarter ended June 30, 2026, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

EDEN PRAIRIE, Minn., Oct. 23, 2026 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE: WGO) (the “Company”), a leading manufacturer of outdoor recreation products, today announced its intent to nominate Jay L. Johnson for election to Winnebago Industries’ Board of Directors (the “Board”) at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”), expected to be held in December.

“We look forward to welcoming Jay to the Board and benefiting from his perspectives as we navigate a dynamic environment and advance Winnebago Industries’ position as a trusted leader in outdoor recreation products,” said John Murabito, Independent Chairman of Winnebago Industries’ Board. “Jay’s expertise in financial management, capital allocation and capital markets will complement the skills and experience of our existing directors.”

In connection with Mr. Johnson’s nomination, Winnebago Industries has entered into a cooperation agreement with Vision One Fund, LP (“Vision One”). Under the cooperation agreement, Vision One has agreed to customary standstill, voting and other provisions. A complete copy of the cooperation agreement will be filed with the U.S. Securities and Exchange Commission as an exhibit to a Current Report on Form 8-K.

In addition, Winnebago Industries announced that the Board has committed to submitting proposals at the 2026 Annual Meeting seeking shareholder approval of amendments to the Company’s Articles of Incorporation and Bylaws to phase out its classified Board structure over a three-year period, beginning with the 2027 Annual Meeting of Shareholders.

The Board’s formal recommendations regarding the election of directors and the proposed amendments to the Company’s Articles of Incorporation and Bylaws will be included in the Company’s definitive proxy statement for the 2026 Annual Meeting, which will also provide the meeting date and other relevant information.

About Jay L. Johnson
Jay L. Johnson has been Executive Vice President, Chief Financial Officer and Treasurer of Lamar Advertising Company since October 2019. Prior to joining Lamar, Mr. Johnson served as Executive Vice President and Chief Financial Officer of DiamondRock Hospitality Company and as Senior Vice President and Treasurer of Host Hotels & Resorts. Prior to Host, he served in a variety of senior leadership roles at KeyBank Real Estate Capital and Bank of America. Mr. Johnson currently serves as a director at SBA Communications Corp., a leading owner and operator of wireless communications infrastructure, and is a former director at Newell Brands, Inc., a global consumer goods company. He received his Masters in Business Administration from Harvard Business School and his undergraduate degree from Morehouse College.

About Winnebago Industries
Winnebago Industries, Inc. is a leading North American manufacturer of outdoor recreation products under the Winnebago, Grand Design, Chris-Craft, Newmar and Barletta brands, which are used primarily in leisure travel and outdoor recreation activities. The Company builds high-quality motorhomes, travel trailers, fifth-wheel products, outboard and sterndrive powerboats, pontoons, and commercial community outreach vehicles. Committed to advancing sustainable innovation and leveraging vertical integration in key component areas, Winnebago Industries has multiple facilities in Iowa, Indiana, Minnesota and Florida. The Company’s common stock is listed on the New York Stock Exchange and traded under the symbol WGO. For access to Winnebago Industries’ investor relations material or to add your name to an automatic email list for Company news releases, visit http://investor.wgo.net.

Advisors

Goldman Sachs & Co. LLC is serving as financial advisor to Winnebago Industries and Sidley Austin LLP is serving as legal advisor. Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated nomination and election of Jay L. Johnson to the Board, the proposed declassification of the Board and the timing and implementation of related governance changes. Forward-looking statements may be identified by terms such as “may,” “will,” “could,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “believe” or similar expressions. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including the outcome of shareholder votes at the 2026 Annual Meeting and other factors described in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Important Additional Information and Where to Find It

The Company intends to file a proxy statement on Schedule 14A, an accompanying proxy card and other relevant documents with the SEC in connection with its 2026 Annual Meeting. SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders may obtain copies of these documents, when available, free of charge at the SEC’s website at www.sec.gov or through the “SEC Filings” section of the Company’s investor relations website at https://winnebago.gcs-web.com/.

Certain Information Regarding Participants in the Solicitation

The Company, its directors and certain of its executive officers (Michael Happe, President and Chief Executive Officer; Bryan Hughes, Senior Vice President – Chief Financial Officer, Investor Relations, Information Technology and Business Development; and Stacy Bogart, Senior Vice President – Chief Legal Officer, Corporate Secretary and Corporate Responsibility) are deemed “participants” (as defined in Schedule 14A under the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s shareholders in connection with the matters to be considered at the 2026 Annual Meeting. Information regarding the names of the Company’s directors and executive officers and certain other individuals and their respective interests in the Company, by security holdings or otherwise, is set forth in the sections entitled “Director Compensation,” “Compensation Discussion and Analysis,” “Compensation Tables and Narrative Disclosure,” and “Security Ownership of Certain Beneficial Owners and Management” of the Company’s proxy statement on Schedule 14A in connection with its 2025 Annual Meeting of Shareholders, filed with the SEC on November 4, 2025 (available here) and the section entitled “Information about our Executive Officers” of the Company’s Annual Report on Form 10-K filed with the SEC on October 21, 2026 (available here) and, with respect to Emily Silver, Item 5.02 of the Company’s Current Report on Form 8-K filed with the SEC on May 1, 2026 (available here). Supplemental information regarding the participants’ holdings of the Company’s securities can be found in SEC filings on statements of beneficial ownership on Forms 3, 4 and 5 filed with the SEC on October 27, 2025 and October 15, 2026 for Sara Armbruster (available here and here); October 13, 2026 and October 16, 2026 for Stacy Bogart (available here, here and here); October 15, 2026 for Christopher Braun (available here); October 15, 2026 for Kevin Bryant (available here); November 17, 2025 and October 15, 2026 for William Fisher (available here and here); October 29, 2025, August 14, 2026, October 13, 2026 and October 16, 2026 for Michael Happe (available here, here, here, here and here); October 13, 2026 and October 16, 2026 for Bryan Hughes (available here, here and here); August 31, 2026 and October 15, 2026 for Staci Kroon (available here and here); December 1, 2025, March 3, 2026 and October 15, 2026 for David Miles (available here, here and here); October 15, 2026 for John Murabito (available here); December 1, 2025, March 3, 2026, June 1, 2026, August 31, 2026 and October 15, 2026 for Michael Pack (available here, here, here, here and here); and May 1, 2026, May 5, 2026 and October 15, 2026 for Emily Silver (available here, here and here). Such filings will also be available at no charge by clicking the “SEC Filings” link in the “Financial Information” section of the “Investors” tab of the Company’s website at https://winnebago.gcs-web.com/.

Any subsequent updates following the date hereof to the information regarding the identity of potential participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Company’s proxy statement on Schedule 14A and other materials to be filed with the SEC in connection with the Company’s 2026 Annual Meeting, when they become available. These documents will be available free of charge as described above.

Contacts

Investors: Joan Ondala
ir@winnebagoind.com

Media: Dan Sullivan
media@winnebagoind.com

or

Joseph Sala / Mahmoud Siddig / Thomas Crosson
212-355-4449
Joele Frank, Wilkinson Brimmer Katcher

Proven distribution leader to sharpen execution, drive improved performance and create long-term shareholder value

ANTIOCH, Tenn., Oct. 23, 2026 (GLOBE NEWSWIRE) — LKQ Corporation (Nasdaq: LKQ) today announced that its Board of Directors has appointed Salvatore A. “Sal” Abbate as President and Chief Executive Officer, effective December 15, 2026. He succeeds Justin Jude, who is departing the Company effective today. Until Mr. Abbate assumes the role of President and Chief Executive Officer, the Company has established an interim Office of the Chief Executive Officer to provide ongoing leadership continuity, consisting of John Mendel, Chairman of the Board, and Sue Gove, Chair of LKQ’s Audit Committee. The Office of the Chief Executive Officer will work closely with LKQ’s leadership teams and management in overseeing the Company’s operations during the interim period.

Mr. Abbate brings more than three decades of experience leading large, complex distribution and industrial businesses. As CEO of Veritiv Corporation, he led a significant transformation of the company, with its share price increasing more than 13-fold during his tenure, culminating in its $2.6 billion sale to Clayton, Dubilier & Rice in 2023. Before becoming CEO, he served as Veritiv’s Chief Operating Officer and Chief Commercial Officer. Earlier in his career, Mr. Abbate held senior leadership roles at Andersen Windows & Doors, Solutia, Inc., now part of Eastman Chemical Company, and Armstrong World Industries, with responsibilities spanning sales, marketing, distribution, logistics, manufacturing, strategy and process improvement.

Mr. Abbate’s experience aligns closely with LKQ’s strategic and operational priorities. He has led high-volume, multi-site distribution businesses where pricing, procurement and supply chain discipline are critical to performance, and has led portfolio transformation focused on margin improvement and cash generation. He also brings public-company and international experience. He currently serves on the board of ArcBest (Nasdaq: ARCB). He holds a bachelor’s degree in industrial engineering from the Georgia Institute of Technology and an MBA from Northwestern University’s Kellogg School of Management.

“After a thorough search, the Board concluded that Sal is the right leader for LKQ at this moment,” said John Mendel, Chairman of the Board. “He is a disciplined operator and people-centered leader, who has transformed a complex distribution business, improved margins and created significant value for shareholders. Sal brings the operating rigor, commercial instincts and sense of urgency we need to sharpen execution across our businesses and unlock the full potential of LKQ. On behalf of the Board, I also want to thank Justin for his years of service and contributions to LKQ.”

“LKQ is an exceptional company, with unmatched scale, leading market positions and a deep bench of talented people,” said Mr. Abbate. “There is meaningful opportunity to improve performance, and I intend to move quickly. That starts with listening to our customers and teams, fostering a culture where our people can succeed and thrive, driving disciplined execution across every region and holding ourselves accountable for results. I’m honored to lead LKQ and look forward to working with the Board and the team to build a stronger, more profitable company.”

About LKQ Corporation

LKQ Corporation (www.lkqcorp.com) is a leading provider of alternative and specialty parts to repair and accessorize automobiles and other vehicles. LKQ has operations in North America, Europe and Taiwan. LKQ offers its customers a broad range of OE recycled and aftermarket parts, replacement systems, components, equipment, and services to repair and accessorize automobiles, trucks, and recreational and performance vehicles.

Investor Contact
Joseph P. Boutross
LKQ Corporation
Vice President, Investor Relations
(312) 621-2793
jpboutross@lkqcorp.com

Media Contact
Whit Clay
Longacre Square Partners
lkq@longacresquare.com

Forward-Looking Statements

Statements and information in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are made pursuant to the “safe harbor” provisions of such Act.

Forward-looking statements include, but are not limited to, statements regarding our outlook, expectations, beliefs, hopes, intentions and strategies. These statements are subject to a number of risks, uncertainties, assumptions and other factors including those identified in our filings with the SEC. All forward-looking statements are based on information available to us at the time the statements are made. We undertake no obligation to update any forward- looking statements, whether as a result of new information, future events or otherwise, except as required by law.

You should not place undue reliance on our forward-looking statements. Actual events or results may differ materially from those expressed or implied in the forward-looking statements. The risks, uncertainties, assumptions and other factors that could cause actual events or results to differ from the events or results predicted or implied by our forward- looking statements include the factors discussed in our filings with the SEC, including those disclosed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025 and in our subsequent Quarterly Reports on Form 10-Q. These reports are available at the Investor Relations section on our website (www.lkqcorp.com) and on the SEC’s website (www.sec.gov).